Realm Therapeutics, a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, has appointed Sanford Zweifach to the company’s board as a non-executive director, effective 1 December 2017.
Zweifach has more than 25 years of experience in the life sciences industry, with an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising.
He is Founder, President and CEO of Nuvelution Pharma, a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a Research and Development risk-sharing approach that deploys capital and human resources.
Prior to Nuvelution, Zweifach held executive leadership roles in the biopharmaceutical industry and life sciences investment banking, including: CEO of Ascendancy Healthcare; Managing Director of boutique investment bank Reedland Capital Partners; CEO and President of biomarker development company Pathway Diagnostics; CFO and Managing Director of Bay City Capital, a sector focused venture capital and merchant banking firm; and President and CFO of Epoch Biosciences Corporation, which was subsequently acquired by Nanogen.
In addition to serving on the Board of Nuvelution, Zweifach currently serves as Chairman of IMIDomics, focused on the discovery and application of biomarkers and targets for immune-mediated inflammatory diseases, and Chairman of Lyric Pharmaceuticals (a company developing novel therapeutics to improve the care of critically ill patients).
He has served on audit and compensation committees. Zweifach holds a Masters of Science in Human Physiology from the University of California (UC) Davis and a Bachelor of Arts in Biology from UC San Diego and is qualified as a Certified Public Accountant with Coopers & Lybrand.
The Company further announced that current Non-Executive Directors, Matthew Hammond and Daniel Hegglin, will retire from the Board, following the successful completion of the company’s recent financing.
Charles Spicer, Non-Executive Chairman of Realm Therapeutics, said: “The Board and I would like to thank Matthew and Danny for their significant contributions to Realm during their tenure, including guiding the transition of the Company to its current drug development focus and the associated divestiture of non-core businesses and repositioning of the business.”
Alex Martin, CEO of Realm Therapeutics, said: “I am excited to welcome Sandy to the Board. His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond. I would like to add my thanks to Danny and Matthew for their support and guidance since I joined the Company.”
